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Abstract 
Neurological diseases of diverse aetiologies have significant effects on the quality of life of patients. The limited 
self‑repairing capacity of the brain is considered to be the origin of the irreversible and progressive nature of many 
neurological diseases. Therefore, neuroprotection is an important goal shared by many clinical neurologists and 
neuroscientists. In this review, we discuss the main obstacles that have prevented the implementation of experi‑
mental neuroprotective strategies in humans and propose alternative avenues for the use of neuroprotection as a 
feasible therapeutic approach. Special attention is devoted to nanotechnology, which is a new approach for develop‑
ing highly specific and localized biomedical solutions for the study of the multiple mechanisms involved in stroke. 
Nanotechnology is contributing to personalized neuroprotection by allowing us to identify mechanisms, determine 
optimal therapeutic windows, and protect patients from brain damage. In summary, multiple aspects of these new 
players in biomedicine should be considered in future in vivo and in vitro studies with the aim of improving their 
applicability to clinical studies.
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Background
The socioeconomic repercussions of neurological dis-
eases are substantial. According to a 2010 study from the 
European Brain Council, the annual cost of neurological 
disease reaches 800 billion Euros per year, 60% of which 
is attributed to direct costs [1, 2]. In Europe, more than 
8 million people have a stroke every year, with an associ-
ate cost of about 64 billion Euros. Considering that the 
ageing European population will rise up continuously, 
the clinical repercussions of neurological disease will also 
have large impacts on our health quality. Alterations of 
the nervous system that directly lead to motor, sensory, 
cognitive, and behavioural changes affect the character of 
the patient.
The limited self-repairing capacity of the brain is con-
sidered to be the origin of the irreversible and progres-
sive nature of many neurological diseases. Therefore, 
neuroprotection may be thought of as a set of interven-
tions used to improve the resilience of the nervous sys-
tem, which is an important goal shared by many clinical 
neurologists and neuroscientists. Research on new drugs 
designed to block the progression of damage in the brain 
parenchyma began more than five decades ago, and the 
first clinical trials were initiated in the 1980s [3–5]. These 
studies have become one of the main sources of knowl-
edge required to understand the nervous system. How-
ever, all of the early approaches failed when they were 
translated in clinical trials. This raised doubts regarding 
the applicability of human neuroprotection strategies 
[6, 7]. In fact, this unsuccessful studies had caused phar-
maceutical companies to stop their research projects in 
neurology [8], although, nowadays scientific evidence 
allows us to ensure that neuroprotection (defined as a 
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combination of strategies, therapies and drugs that may 
result in salvage, recovery or regeneration of the tissue 
loss, its cells, structure and function) is definitely feasible 
irrespective of the difficulties in finding the optimal con-
ditions for clinical applications [9, 10].
In this paper, we review the main obstacles that have 
prevented the implementation of experimental neuro-
protective therapeutics in humans and propose alterna-
tive avenues to bring back neuroprotection as a feasible 
therapeutic approach. Special attention will be devoted 
to nanotechnology as a new approach used to develop 
highly specific and localized biomedical solutions for 
multiple mechanisms involved in stroke. Nanostructures 
have been shown to be powerful and innovative tools in 
materials science, electronics, energy, and environmen-
tal science. Recently, nanostructures have been shown to 
have unexpected utility in biomedical applications, both 
for imaging and therapeutic development.
Broadening the concept of neuroprotection
In the short period of time immediately after the reduc-
tion in cerebral blood flow in a particular brain region 
(from seconds to minutes), there are a series of sequen-
tial processes, such as biochemical, metabolic, and cel-
lular alterations that eventually lead to tissue necrosis. 
This necrotic area, denominated core, will be surrounded 
by damaged, but potentially recoverable tissue, called 
ischemic penumbra [11].
Traditionally, neuroprotective studies have focused on 
protecting cells from damage by identifying drugs that 
are capable of blocking one or more components of the 
neuronal ischemic cascade in the penumbra [12, 13]. Of 
course, these concepts must be reviewed. Cellular death 
cascade begins in the ischemic penumbra area and affects 
neurons, other brain cells like astrocytes, oligodendro-
cytes, microglia and vascular cells like endothelial cells, 
pericytes, and smooth muscle cells. In addition, this cas-
cade interferes with the interactions between brain cells 
and the extracellular matrix. Thus, the identification of 
neuroprotective targets for the treatment of cerebral 
ischemia must extend from the exclusive and limited 
neuronal damage that is observed, to the broad recovery 
of all neurovascular networks [14].
The evolution of the penumbra to viable tissue or to 
progressive destruction is conditioned by biochemical 
mechanisms triggered by cerebral ischemia, which in 
turn critically depends on excitotoxicity, oxidative stress, 
and inflammation. These pathophysiological responses 
affect not only neurons, but also the entire neurovascu-
lar system. Their impact and intensity vary over time, 
even during the acute phase of cerebral ischemia. These 
responses may lead to further destruction or protection, 
even within the same cell line [14–19].
Glutamate acts not only as a neurotransmitter, but also 
as a signalling system between the different cell types of 
the nervous system. The high level of extracellular glu-
tamatergic excitotoxicity [20] in cerebral ischemia is due 
to increased glutamate release by neurons [21], the fail-
ure of astrocytic glutamate uptake, and disruption of the 
glutamate-glutamine cycle [22]. Moreover, since oligo-
dendrocytes express N-methyl-d-aspartate (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors, their associated toxicity blocks signal-
ling between myelin and axons, contributing to neuronal 
injury [23]. Pericytes [24] and endothelial cells [25] also 
have glutamate receptors and are susceptible to excito-
toxic damage. One possible reason for the clinical failure 
of glutamate antagonists may be their focus on neuronal 
NMDA receptors [26]. It may be that a more universal 
approach to reducing the concentrations of extracellular 
glutamate through non-specific receptor mechanisms 
would be a more promising alternative [27].
Oxidative stress increases mitochondrial perme-
ability, causes oedema and mitochondrial damage, and 
ultimately leads to neuronal death. Free radicals are pro-
duced in large amounts in ischemic tissue, especially 
after reperfusion. This occurs both when the reperfusion 
is spontaneous and when it is induced as a part of a ther-
apeutic approach. The astrocytes in turn release antioxi-
dants that help neuronal survival [28].
Endothelial cells are an important source of nitric oxide. 
This compound, under normal conditions, promotes 
increases in blood flow. However, in the presence of other 
radicals, nitric oxide can be converted into peroxynitrite, 
which is capable of destroying cellular membranes [29]. 
Cerebral white matter, which has high lipid content, is 
another important source of free radicals, and contributes 
to oxidative damage of oligodendrocytes around neuronal 
axons. In addition, oxidative stress prevents from mye-
linogenesis and post-ischemia axonal recovery [30].
The inflammatory response is characterised by the 
accumulation of cells and inflammatory mediators in the 
ischemic brain and is responsible for endothelial dam-
age and blood brain barrier (BBB) breakdown in the early 
course of ischemia [31]. This disruption facilitates the 
recruitment of inflammatory cells, the microglia activa-
tion, and neuronal destruction [32]. Microglia and other 
inflammatory cells in the brain express toll-like receptors, 
which are able to recognize damage-associated molecular 
pattern molecules (DAMPs), which induce the expres-
sion of inflammatory mediators, adhesion molecules and 
the activation of innate immunity [33, 34]. Reactive astro-
cytes also increase the production of pro-inflammatory 
cytokines blocking axonal recovery. Pericytes are also 
inflammatory mediators that, at the same time, induce 
further DAMP release [19, 35].
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Exosomes are nanovesicles (40–100  nm) excreted by 
all brain cells. They contain lipids, proteins, and nucleic 
acids, which are essential for communicating between 
non-contiguous cells [36]. They are incorporated into 
target cells, where they modify or reprogram cellular 
activity depending on their contents. During cellular 
ischemia, some inflammatory mediators stimulate exo-
some production by endothelial cells [37]. Astrocytes, 
oligodendrocytes, microglia, and neurons are connected 
via exosome release, which has as yet unknown functions 
in many cases. Oligodendrocytic exosomes release inter-
feres with oligodendrocytic control of microglia and pro-
vokes microglial activation [38–40].
Simplistic neuroprotective approaches that ignore the 
complex and interrelated cellular universe (Fig.  1) con-
stituting the neurovascular system have little chance of 
success. Even though cell survival is necessary, it is not 
sufficient for complete structural and functional recov-
ery after stroke. Thus, in addition to neuroprotection, it 
is crucial to ensure that the area surrounding the lesion 
has the appropriate conditions needed for restoration of 
cellular function in the affected region.
Does neuroprotection still have a chance?
Intravenous thrombolysis administered within 4.5 h after 
the onset of ischemic stroke symptoms is probably the 
best therapeutic approach for patients at this time. Mar-
ket pressure makes it difficult to compare this treatment 
to other non-pharmacological procedures, or even other 
alternative therapies. However, after 20  years of clinical 
experience and enormous economic investment, intra-
venous thrombolysis is applied only in 0.4–3% of cases 
in developing countries [41, 42], and in 2–7% of cases in 
most developed countries [43]. Revascularization treat-
ment will certainly become more effective (and more 
expensive and difficult to sustain) in the future [44–46], 
but will probably not become a universal treatment [47].
Considering the above, it is necessary to insist on the 
development of neuroprotection as a treatment com-
plementary to the at most 10% of patients who undergo 
revascularization treatment. Most importantly, neuro-
protection should be developed as an alternative therapy 
for the 90% of patients that cannot be treated with revas-
cularization therapy. An outcome improvement of 5 for 
100% of patients will have more significant clinical and 
Fig. 1 Cellular and intercellular complex of the neurovascular system and joint mechanisms of the ischemic cascade. Continuous and dashed lines 
indicate toxic and protective effects, respectively, during the acute phase of cerebral ischemia
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socioeconomic repercussions than an outcome improve-
ment of 40 in 10% of the target population.
In preclinical studies, neuroprotection has been shown 
to be more effective in models of ischemia that are fol-
lowed by artery reperfusion [5]. This has led to the pos-
tulate that neuroprotection may be appropriate only if 
cerebral perfusion is restored. However, if we restrict the 
use of neuroprotection to cases with restored perfusion, 
the added value of this approach to stroke treatment 
will be minimal and possibly limited to the inhibition 
of the oxidative stress effects after reperfusion [48]. 
Despite of findings that demonstrate the requisite close 
correlation between early recanalization and late clini-
cal outcomes of direct relevance to the patient [49–53], 
the close relationships between recanalization, clinical 
benefit, and the pathophysiological changes second-
ary to reperfusion, have not yet entirely been elucidated 
[54, 55]. Firstly, in some cases there is no demonstrated 
association between recanalization frequency and clini-
cal benefit (intra-arterial thrombolysis and mechanical 
thrombectomy lead to more recanalization, but both fail 
to improve clinical outcomes) [56–59]. Secondly, optimal 
collateral circulation may protect the brain parenchyma, 
even in the absence of recanalization [60]. Thirdly, early 
recanalization only confers clinical benefit to one-third 
of treated patients [61]. Fourthly, recanalization may 
exacerbate the tissue damage following hyperperfusion, 
cerebral oedema, and secondary haemorrhagic trans-
formation [62]. Fifthly, reperfusion may not occur even 
when complete recanalization is achieved due to a few 
known mechanisms, which lead the phenomenon of 
“non-reflow” [63]. Finally, spontaneous recanalization 
is not an exceptional phenomenon, but occurs in 25% of 
patients during the first 24 h and in 50% of cases during 
the first week [55].
Therefore, neuroprotection remains a necessary oppor-
tunity for not only more than three-quarters of patients 
who will not benefit from a proper and safe recanaliza-
tion treatment, but for all patients with ischemic stroke.
The therapeutic window of neuroprotection
The establishment of therapeutic windows for differ-
ent neuroprotective (or even recanalization) treatments 
is dependent on regulatory requirements, but does not 
always follow scientific evidence. The mantra “time is 
brain” has become an indisputable truth, but is not neces-
sarily related to the pathophysiology of cerebral ischemia 
and it application may be different from one patient to 
another [64]. The administration of neuroprotective 
drugs, recanalization, or repair of injured tissue may be 
not mislead with the indisputable importance of a neuro-
logical diagnosis and specialized care as soon as possible 
in patients with suspected ischemic stroke.
Cerebral ischemia is a dynamic process during which 
time is not discontinuous, but is associated with continu-
ous individualized hemodynamic, cellular, and molecular 
changes [65]. Therefore, not all therapeutic procedures 
may be indicated in all individuals at the same time. The 
onset of symptoms does not always coincide with the 
timing of vascular occlusion. Instead, a balance between 
the occlusion and suitable collateral circulation deter-
mines the onset of clinical signs. A progressive occlusion 
may allow the development of an intense collateral cir-
culation that nullifies or minimizes neurological deficits. 
On the other hand, an acute occlusion does not facilitate 
collateral flow, and as a consequence, sharply damages 
the cerebral parenchyma [64].
Recanalization treatment, although patient specific, 
is time-dependent [66], and has molecular and clinical 
markers, including those obtained using medical imag-
ing, that allow the clinician to determine the best timing 
for individual treatment [67–69]. However, the therapeu-
tic window for neuroprotective drugs may be different 
depending on whether the main goal is to control exci-
totoxicity, oxidative stress, or inflammation. The inhi-
bition of post-ischemic inflammation in a very narrow 
therapeutic window has reduced effectiveness, similar to 
using glutamate grabbers many hours after the onset of 
symptoms (Fig. 2). In brief, the current challenge is rec-
ognize that the best therapeutic timing for a neuropro-
tective drug will be different depending on the affected 
brain area and treatment target.
Dynamic and heterogenic ischemic 
pathophysiology
Recent studies have demonstrated that the components 
of the neurovascular unit have heterogenic character-
istics, not only in morphology, function, gene expres-
sion, and physiological properties, but also in their 
responses to different diseases [70–72]. This heterogene-
ity may explain why these cells have developed harmful 
or protective responses at different times after cerebral 
ischemia [15].
The cellular and molecular responses that are observed 
during cerebral ischemia (Fig. 3) are sequential processes 
that progressively affect different cellular elements that 
may then determine downstream molecular responses, 
which are sometimes antagonistic. This possible limita-
tion is one of the responsible of the development of the 
personalized medicine in this pathology. Therapy must 
be adapted to the cellular or process goal in function of 
time and the affected region. Once cerebral perfusion is 
reduced below the ischemic threshold, neurons initiate 
a calcium-dependent destructive process, and as a con-
sequence release large amounts of glutamate and induce 
astrocytic reactivity. These reactivated astrocytes promote 
Page 5 of 15Da Silva‑Candal et al. J Nanobiotechnol  (2017) 15:30 
progressive tissue destruction by inhibiting glutamate 
uptake, releasing pro-inflammatory cytokines, and devel-
oping a glial scar, which will prevent ischemic injury repair. 
However, in a complementary manner, the stimulated 
astrocytes activate mechanisms that increase cerebral 
blood flow, stimulate genes needed for regulating neuronal 
synaptogenesis or the secretion of trophic factors, and 
contribute to BBB repair and myelinogenesis [70–75].
The breakdown of the blood brain barrier, which is 
secondary to endothelial dysfunction, is another key 
component in ischemic brain damage [76]. Neverthe-
less, damaged endothelial cells are able to stimulate 
neurogenesis, oligodendrogenesis, and the angiogenesis 
mediated by progenitor endothelial cells. Through their 
close relationship with pericytes, they play a key role in 
replenishing the blood brain barrier, in the synthesis of 
the extracellular matrix, and in angiogenesis [35, 77–81].
Ischemic injury to the white matter is an important 
source of free radicals and oxidative stress damage. Here, 
oligodendrocytes will provide essential substrates for 
axonal recovery, and together with endothelial cells, will 
contribute to angiogenesis and oligodendrogenesis [82, 
83].
Microglia has contradictory functions, which may 
either be cytoprotective or cytotoxic, during cerebral 
ischemia, as they release pro-inflammatory or anti-
inflammatory molecules, attenuate or stimulate neu-
rogenesis, and inhibit or promote phagocytosis. The 
reasons for this phenotypic heterogeneity are not yet 
well-understood [84, 85].
Fig. 2 a Molecules expressed in a rat ischemia–reperfusion model. Temporal expression of heat shock protein‑72 (colour‑coded density maps 
overlaid on magnetic resonance images). The highest expression level is found in the cerebral cortex between 6 and 12 h after occlusion. b Tempo‑
ral expression of glutamate (colour‑coded spectroscopic maps). The maximum concentration occurs at 30 min following occlusion at the nucleus 
of the lesion, while the peak glutamate concentration in the periphery of the infarction occurs at 6 h after occlusion (Reproduced from [107] by 
permission of Stroke)
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The cellular and extracellular behaviours of the neu-
rovascular union and the molecular expression changes 
during cerebral ischemia (Fig. 3) sometimes have a dual 
nature. The activation of NMDA receptors, which are 
responsible the early excitotoxicity peak, is essential for 
neuronal plasticity [15, 16]. Oxidative stress is involved 
in cellular membrane destruction, but is essential for 
mediating the release of trophic factors and oligoden-
drogenesis [86]. Perhaps the paradigm of heterogeneous 
molecular reactions lies within inflammatory molecules. 
Cerebral ischemia triggers an inflammatory response, 
which is mostly responsible for cellular necrosis and 
the breakdown of the blood brain barrier. However, 
this response is also crucial for cellular repair and the 
regeneration of the affected parenchyma. Recently, sev-
eral studies have demonstrated that persistence of the 
inflammatory response may be responsible for neurode-
generative processes after stroke [19, 87–93].
Consequently, the dynamic and heterogenic charac-
teristics of ischemic process are the main responsible of 
the development of the personalized medicine. Future 
therapies must be designed taking into account different 
parameters as cellular or process goal, time and affected 
regions.
Personalized neuroprotection
There are many variables that have led to the failure of 
neuroprotection as an alternative therapy in nervous sys-
tem diseases, particularly in stroke. In this work, we have 
discussed the complexity of cellular and molecular mech-
anisms during cerebral ischemia. This complexity under-
lies the difficulty of achieving universal neuroprotection. 
Fig. 3 Time‑courses of cellular (a) and molecular responses (b) during the chronological evolution of cerebral ischemia. Each of the cells involved 
and the secondary molecular expression patterns can play a bi‑ or tri‑phasic role. These roles may sometimes be interrelated
Page 7 of 15Da Silva‑Candal et al. J Nanobiotechnol  (2017) 15:30 
To overcome this obstacle, several approaches have been 
proposed. These include the use of combined treatments 
with additive or synergistic benefits or treatments with 
pleiotropic effects [10]. However, these options have not 
yet been effective.
Given the urgent need to improve neuroprotective 
approaches, it seems necessary to develop customized 
strategies that facilitate access to specific targets at the 
right times. This ambitious goal requires the development 
of biomarkers to quickly evaluate the stage of molecular 
mechanisms and drug-carrying devices that can cross the 
intact blood brain barrier and reach the affected areas of 
the brain parenchyma.
Neuroscience research in the last decade has been 
focused on the development of biomarkers for diagnosis, 
treatment, and prognosis after stroke. However, few of 
these biomarkers, if any, have been applied in clinical set-
tings. In addition, only a few clinical trials have included 
the use of biomarkers [94]. Nevertheless, all of these 
studies and their results have contributed to a better 
understanding of the pathophysiology of brain ischemia.
One of the main factors reducing the translation of 
biomarkers of excitotoxicity, oxidative stress, inflamma-
tion, endothelial dysfunction, apoptosis, etc. is that they 
are time-dependent. One limitation of the use of these 
biomarkers is that they may reflect the effects of the 
damage rather than the mechanisms responsible for the 
damage at the time of their determination [95]. Another 
limitation is the low sensitivity and low specificity of 
the biomarkers used so far. Neurons, astrocytes, micro-
glia, oligodendrocytes, endothelial cells, and pericytes 
all secrete the same biomarkers, even though they may 
have antagonistic functions depending on their energetic 
availability or their particular localization within the 
damaged or healthy brain parenchyma [96]. Immediately 
after ischemia, excitotoxicity reaches a maximum at the 
core of the lesion, which is a region of reduced thera-
peutic interest. However, excitotoxicity is delayed in the 
penumbra [97, 98]. In perfused tissue, there are high lev-
els of oxidative stress, which are associated with better 
outcomes. In addition, identical inflammatory biomark-
ers in this region may have opposite effects depending on 
timing, localization, cell type, and the hemodynamic situ-
ation [87, 89, 99–101]. On the other hand, not all these 
biomarkers are secreted to the blood stream, some of 
them are only expressed on the surface of affected cells 
being unable to perform a direct detection trough non-
invasive techniques like blood extraction.
Since stroke is a heterogeneous and time-dependent 
disease, the identification of a unique biomarker that can 
reflect all of the complicated pathophysiologic processes 
is difficult. The combination of several biomarkers and 
their evolution in time would probably provide precise 
an specific information regarding what is happening in 
the affected region during and after ischemia [102]. To 
achieve this objective and to move further toward per-
sonalized neuroprotection, there is a need for new clini-
cal [103] and preclinical [104] perspectives that can lead 
to the development of useful and accurate biomarkers. 
The detection of serum or cerebrospinal fluid biomarkers 
are a well-established method for diagnostic and to check 
the evolution of many diseases such as ischemic stroke 
or Alzheimer [68, 102–106], but is limited to soluble bio-
markers in blood suspension that can be extracted from 
the patients multiple times, that hardly reduces the diag-
nostic of many diseases that doesn’t meet these require-
ments like the extracellular expression of an specific 
protein related to an specific pathology that is not fully 
excreted to blood stream and consequently undetectable. 
In this way, nanoparticles are a powerful tool for both 
treatment and diagnostic [107]. A nanoparticle com-
posed by a contrast agent/radiolabel and functionalised 
with antibodies against an specific target in cell surfaces 
allowing to assess the evolution/detection in a non-inva-
sive way. Also, if this is combined with drug encapsula-
tion, allows an specific and local treatment that increases 
drug efficiency and dose reduction limiting secondary 
effects. A dual methodology combining nanotechnology 
and common biomarkers could highly improve diagnos-
tic and treatment in neurological disease, which repre-
sents the basis of the concept of personalized medicine.
Another element that may lead to misleading inter-
pretations of biomarkers during cerebral ischemia is the 
BBB. Normally, the main function of the BBB is to pro-
tect the central nervous system from the entrance of 
drugs. However, this role may be reversed, and the BBB 
may modulate biomarker release from the brain to the 
general circulation [107–109].
The time-evolution of blood–brain-barrier perme-
ability after acute ischemic stroke is a controversial and 
not well understood issue in humans. Briefly, although 
research works present controversy about the perme-
ability window (from 1, 4, 24 and 48  h from the onset 
of the lesion up to 1 week), all studies agree that during 
the acute phase of stroke, a transitory breakdown of the 
BBB occurs, which facilitates the systemic infiltration to 
the ischemic surrounded area [110]. The concentrations 
of these molecules depend on their cerebral concentra-
tion but also on the degree of BBB dysfunction. Thus, the 
optimal combination of molecular [111–113] and neu-
roimaging [114] biomarkers would help in elucidating 
the integrity of the BBB and therefore to understanding 
changes in the concentrations of biomarkers in plasma.
It should also be noted that one of the biggest chal-
lenges in the study of neuroprotection in stroke is the 
translation of animal studies to human trials. Different 
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treatments that produce positive results in rodents have 
failed to provide significant benefit in clinical trials. 
Detailed discussion of animal stroke models and their 
application in clinical studies can be found in several 
research works [115–118]. Briefly, recreating all features 
of human stroke in an animal model is not feasible due 
to complexity of the disorder. Some of the factors that we 
should be considered for the personalized neuroprotec-
tion therapy development include age and medication 
use history of the patient, infarct size, location and col-
lateral circulation. In this line, choosing an appropriate 
animal stroke model and optimizing the study design 
increase the translation from animal research to clinical 
applications.
Last, research and clinical works indicate that person-
alized neuroprotection will be in the next years a real-
ity as a consequence of a process of adaptation to the 
nanotechnology, which has proven to be an innovative 
approach for diagnostic and drug delivery therapies.
Nanotechnology for the diagnosis of different 
developmental stages of ischemic stroke
A key for the development of an efficient neuroprotective 
therapy is the early identification of specific brain regions 
that can be treated using a particular approach. In the 
past several centuries, and up to the 1970s, the diag-
nosis of stroke was based exclusively on clinical symp-
toms. In fact, most of the extraordinary progress that 
has been made in recent years is due to our exceptional 
ability to visualize the brain. Neuroimaging has enabled 
the accurate determination of structural and functional 
alterations in the nervous system. However, conventional 
techniques often have several restrictions that limit the 
information provided. These include reduced biomarker 
sensitivity and specificity for identifying and classifying 
disease, short half-lives of contrast agents after systemic 
administration, and the physical restrictions of the BBB 
[119]. Molecular magnetic resonance imaging  (MRI) 
techniques with lower anatomic resolutions have proven 
more effective than structural imaging techniques in the 
study of nervous system function [120].
The use of neuroimaging tools combined with nano-
particles has improved the resolution of the current diag-
nostic procedures. Nevertheless, recent advances in the 
synthesis and functionalization of these nanoparticles are 
now leading to the development of much more specific 
diagnostic approaches for the nervous system [119].
Iron oxide nanoparticles have been extensively inves-
tigated as magnetic resonance contrast agents for last 
two decades, and several types of these particles, such as 
ferumoxytol, have been approved by the Food and Drug 
Administration for use in clinical practice [2]. In par-
ticular, the use of multifunctional superparamagnetic 
iron oxide nanoparticles (SPIONs) has gained grow-
ing interest for use in clinical applications. In general, 
SPIONs have an iron oxide core (approximately 10 nm) 
coated with biocompatible polymers and can be classi-
fied as cross-linked iron oxide nanoparticles (CLIONs, 
50–180  nm), ultra-small superparamagnetic iron oxide 
nanoparticles (USPIONs, 10–50  nm), and very-small 
superparamagnetic iron oxide nanoparticles (VSPI-
ONs, <10 nm). All of these SPIONs have the potential to 
cross the BBB due to them special properties, long half-
lives in blood circulation, and reduced toxicity, besides 
this, interactions with plasma proteins (formation of the 
protein corona) and other blood components could play 
a pivotal role crossing the BBB by increasing the size and 
modifying the charge. Because of this interaction studies 
are mandatory in order to make sure particles preserve 
their functionalization properties in biological fluids 
[121, 122]. SPIONs are eventually eliminated by mac-
rophages, unless they are modified to increase half-lives 
in blood circulation and due to their inherent magnetic 
properties, can be visualized in T2- and T2*-weighted 
MR images [123].
Multifunctional modifications of magnetic nanopar-
ticles or their bioconjugation to antibodies, peptides, 
aptamers, or other specific molecules, will allow for nan-
oparticle vectorization and their accumulation in par-
ticular regions. This technology enables the identification 
of specific regions in the brain parenchyma affected by 
particular pathophysiological or pathogenic mechanisms. 
This may then be used to focus drug delivery within the 
optimal therapeutic window [124]. This hypothesis is 
now under investigation (Fig. 4).
Iron oxide nanoparticles have already been used as 
selective markers for P-selectin and other adhesion mol-
ecules and have allowed the detection of early inflam-
matory responses in animal models of brain ischemia 
[125, 126]. For instance, liposomes loaded with gado-
linium and labelled with antibodies against heat shock 
protein-72, which is a chaperon that is expressed at high 
concentrations in the ischemic penumbra [127], have 
allowed the MRI visualization of the peri-infarct region 
a few hours after the occlusion of the middle cerebral 
artery [128, 129] (Fig. 5). The development of future mul-
tifunctional nanoplatforms will open the doors for more 
sensitive and specific biomarkers that can be used for a 
more accurate diagnosis and eventually the identification 
of potential therapeutic targets [130]. However, param-
eters such as biodistribution, pharmacokinetics, and tox-
icity of these nanoplatforms must be addressed first. In 
this sense, novel nanosystems will have to be non-toxic, 
biocompatible, biodegradable, and easily detectable at 
reduced concentrations. Therefore, it is important to note 
that currently there are laying the foundation of future 
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personalized medicine for the diagnosis and treatment 
of ischemic stroke, however we consider that combin-
ing time-accurate biomarkers and adequate drug deliv-
ery systems able to cross the BBB are the main imminent 
needs to improve.
Nanotechnology for the treatment of ischemic 
stroke and for cell tracking
In addition to new safe and efficient diagnostic tools, 
nanoneuromedicine may be used to develop new thera-
peutic approaches for nervous system diseases that have 
so far been untreatable [124].
Nanotechnology operates at the same length scale as 
natural processes involving viruses, cells, and bacteria, 
and allows us to interact with these biological entities 
in a very specific and localized manner. This has opened 
the door for new approaches in drug administration. For 
example, drugs can be dissolved, mingled, encapsulated, 
or linked to nanoparticles, and then delivered and moni-
tored within a specific region of the body.
Nanoparticles with sizes ranging from 1 to 100 nm are 
capable of interacting with biological systems at a molec-
ular level. They are even able to encapsulate or establish 
stable complexes with a variety of drugs. Drug/molecule 
nanoencapsulation increases the efficacy, specificity, 
and tolerance for drugs (due to the reduced amount of 
drugs required and that nanoparticles are able to modify 
pharmacokinetic properties of treatments). Therefore, 
nanoencapsulation further increases the therapeutic 
benefits of drugs. In addition, drug encapsulation can be 
used to delay or even stop drug degradation during inter-
actions with the biological environment. Drug encap-
sulation may also facilitate the absorption of drugs and 
increase their cellular penetration [131].
Multiple nanoparticles have been tested for drug 
delivery. Nanocarriers can be classified into two groups, 
reversible and non-reversible carriers [132]. Liposomes 
and micelles are the best known reversible nanocarriers 
and their supramolecular complexes are generated on 
the basis of non-covalent intermolecular interactions. 
However, changes in environmental conditions usually 
result in disaggregation of the molecular units that form 
the particle, making them less suitable for preparations 
of stable commercial products used by the pharmaceu-
tical industry. On the other hand, the broad family of 
non-reversible nanoparticles, including nanospheres, 
nanocapsules, dendrimers, metal and magnetic nano-
structures, carbon nanotubes, and mesoporous materials 
Fig. 4 Schematic representation of different types of nanoparticles used for diagnosis and as drug delivery systems
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[133–135] have strong molecular interactions, which 
allow them to have a high degree of chemical stability. 
This in turn facilitates their manufacturing for commer-
cial purposes [12] (Fig. 4).
Nanostructures have the potential to cross the BBB. 
Although the BBB is disrupted during the acute phase 
of stroke and transport across the BBB is not regulated 
during the subacute phase or the chronic stage of the dis-
ease, adequately coated nanoparticles are able to pierce 
the intact BBB by cell-mediated transcytosis mechanisms 
and perform brain-localized drug delivery [134, 136, 
137].
How the nanostructure encapsulated drug, vector-
ized through the corresponding biomarker, could reach 
the ischemic territory, hence, provide diagnosis and/or 
treatment for ischemic stroke may seem insurmount-
able obstacle during the ischemic disease process. How-
ever, it is well known that cerebral collaterals are vascular 
redundancies in the cerebral circulation that can partially 
maintain blood flow to ischemic tissue when primary 
conduits are blocked [138]. Thus, after occlusion of a 
cerebral artery, anastomoses connecting the distal seg-
ments of the middle cerebral artery occlusion (MCAo) 
with distal branches of other cerebral arteries allow for 
partially maintained blood flow in the ischemic penum-
bra and delay or prevent cell death. Therefore, even with-
out a complete arterial reperfusion, nanoparticles can 
potentially get the core or peripheral ischemic territory 
to achieve the designed proposed. In addition, the use of 
nanoparticles has been also combined with thrombolytic 
treatments [139] with the aim to improve the efficacy 
of arterial reperfusion and reduce the risk of bleeding. 
In this regard, the use of nanotechnology in combina-
tion with thrombolytic and neuroprotective treatments, 
for instance, may overcome the application of the nano-
technology on those stroke condition where the cerebral 
artery remains still occluded.
Nanostructures differ in sizes (ranging from nanom-
eters to micrometers), shapes (from spherical, hemi-
spherical, cylindrical, and even conical), surface and 
composition [140]. In the same line, to clinical appli-
cation in ischemic stroke, we must take into account 
the main characteristics of the nanoparticles required 
to traverse the BBB, which are listed below [141, 142]: 
diameter less than 100  nm, be non-toxic, biodegrad-
able and biocompatible, be stable in blood, have pro-
longed circulation time, not activate neutrophils, not 
lead to platelet aggregation, be BBB-targeted and con-
trolled drug release. Several studies have demonstrated 
that these nanoparticles can be transported by axons. In 
addition, it has been shown that after nasal administra-
tion, iron oxide nanoparticles are found in the olfactory 
bulb, striatum, hippocampus, cerebral spine, cerebellum, 
and frontal cortex [143]. This may open the door for new 
administration routes.
Carbon nanotubes have a wide range of chemical, elec-
trical, and mechanical properties, and have been previ-
ously reported to be powerful antioxidants [144] and 
promising scaffolds for tissue repair [134, 145, 146].
In addition to different nanostructures based on ther-
moreversible polymers or liposomes designed to ensure 
enhanced drug delivery control, mesoporous nanopar-
ticles have lately attracted intense attention due to their 
chemical versatility and textural properties. The highly 
interconnected and ordered pores of these materials 
allow them to store huge amounts of drugs and main-
tain their pharmacological properties for long periods 
after their administration. In addition, they offer a free 
surface for functionalization with specific tagging agents 
allowing for further vectorization functionality. Moreo-
ver, high biocompatibility, biodistribution, and excretion 
through the digestive system [147–150], as well as the 
ability to undergo cellular internalization by endocytosis 
without provoking cell alterations (Fig. 6), are additional 
properties that make these materials highly desirable for 
biomedical applications.
Fig. 5 Volume of the residual lesion after transient middle cerebral 
artery occlusion (tMCAo) (1 h) using citicoline alone, citicoline 
encapsulated in non‑vectored liposomes, or citicoline vectored with 
antibodies to the heat shock protein‑72 expressed in the area of the 
ischemic penumbra (Adapted from [129] by permission of Theranos-
tics)
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Another emergent therapeutic modality is stem cell 
therapeutics, which is designed to promote tissue repair 
after stroke. This therapeutic strategy has two aims: to re-
establish the different cellular populations, and to restore 
neurological function. Nevertheless, recent studies have 
shown that the mechanisms of action of stem cells are still 
not well-understood, as these cells may be involved in neu-
rotrophic factor secretion, immunomodulation, endog-
enous neurogenesis stimulation, or neovascularization 
[150]. Likewise, nanomedicine may be viewed as a neces-
sary complement of cell-based therapies due to excellent 
biocompatibility, ease of cellular internalization, and in vivo 
cell tracking possibilities. Nanomedicine may be a potential 
drug delivery platform used to induce specific differentia-
tion- and cell-oriented therapeutics [148, 151–154].
The next step in stem cell therapy research is the 
development of new in  vivo multimodal, non-invasive, 
and sensitive procedures to study the biodistribution, 
survival, migration capacities, and proliferation of the 
administered cells.
The optimum nanoparticles for use as contrast agents 
must be detectable by MRI at reduced doses, should cross 
the BBB, must be non-toxic, and must have no effects on 
cellular viability, mobility, and differentiation, and pre-
serve cellular functions [149, 155–157]. Unfortunately, 
cell tracking presents several problems. For instance, it is 
not possible to distinguish between internalized iron in 
healthy stem cells and the iron signal from apoptotic cells 
or even macrophages using MRI. An ideal nanoparticle 
would have an MRI signal that disappears upon cellular 
death [158].
Finally, multiple concerns will need to be overcome 
before engineered nanomaterials for targeted drug deliv-
ery can become a reality in everyday clinical practice. 
As we have previously mentioned, nanoparticles have 
different features with broad and diverse functionalities 
depending upon their application. Issues such as large-
scale production, cost-effectiveness, the potential tox-
icity of new nanomaterials, time of release, dose, and 
route of administration (oral, intraarterial, intravenous) 
are hot topics in current state-of-the-art nanomedicine 
[159].
Conclusions
Neuroprotection is still an important objective in stroke 
research. Despite all of the advances in endovascular-
perfusion therapy, the practical application of these tech-
niques will always be highly limited for most patients. 
However, neuroprotection has the potential to be more 
universal if we are able to identify sensitive and specific 
biomarkers that reflect the temporal profile and local 
distribution of the pathophysiological mechanisms of 
stroke. Nanotechnology is already contributing to the 
field of personalized neuroprotection and has allowed us 
to identify the mechanisms underlying cerebral damage 
and determine optimal therapeutic windows for stroke 
in order to prevent patients from exposure to irrevers-
ible damage. In summary, we consider that these new 
methodologies may improve the treatment of stroke in 
the next future with a precise diagnosis of spatio-tem-
poral evolution of ischemic lesion; identification of spe-
cific regions, classify domains and accurately identify the 
Fig. 6 a Mesoporous nanostructures and b iron oxide‑functionalised mesoporous nanoparticles. c In vitro tolerance. d Magnetic resonance T2*‑
weighted image of one brain slice of a Wistar rat after mesenchymal cell administration labelled with dextran‑coated superparamagnetic nanoparti‑
cles (D‑MNPs) (Adapted from [157] by permission of Scientific Reports)
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therapeutic window. Future perspectives will bring com-
bination therapy for neuroprotection with more than one 
drug, administration route, cell line or strategy as sys-
temic and focal hypothermia. Treatments will be more 
direct, effective and specific, with fewer side effects, and 
consequently the potential beneficiary patients will be 
considerably increased. Multiple aspects of these new 
players in biomedicine should be considered in future 
further in  vivo and in  vitro studies in order to improve 
their applicability in clinical studies.
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